HERBAL MONOGRAPHS EUROPEAN MISTLETOE/293PRECAUTIONS AND ADVERSE REACTIONS
EUROPEAN MISTLETOE FRUIT
No health hazards or side effects are known in conjunction
with the proper ^administration of designated therapeutic
dosages. The berries are said to have emetic and evacuant
effects and to have caused the death of children. However,
unambiguous proof for these effects does not exist.EUROPEAN MISTLETOE STEM
No health hazards or side effects are known in conjunction
with the proper administration of designated therapeutic
dosages.EUROPEAN MISTLETOE HERB
No health hazards are known in conjunction with the proper
administration of designated therapeutic dosages. The drug is
non-toxic with peroral administration. Local reactions can
occur with parenteral administration of European Mistletoe
extracts such as wheal formation, possibly also necrosis,
chills, fever, headache, anginal complaints, orthostatic circu-
latory disorders and allergic reactions.The wheal formation and the elevation of body temperature
are considered signs of immune system stimulation and
therefore as positive therapeutic effects.DOSAGE
EUROPEAN MISTLETOE HERB
Mode of Administration: Whole, cut and powdered herb are
available in the forms of juice, coated tablets, drops, oil
preparations, ampules and compound preparations.Preparation: A medicinal tea is prepared using 2.5 gm (1
teaspoonful) finely cut drug with 1 cup cold water, steeped
for 12 hours at room temperature, then strained. European
Mistletoe wine is prepared by adding 40 gm drug to 1 liter
wine; the preparation is ready for use after 3 days.A liquid extract is made in the ratio of 1:1 with diluted
ethanol; a tincture is made in the ratio of 1:5 with 45%
ethanol.Daily Dosage: The recommended daily dose is 10 gm drug.
The dosage of medicinal tea is 1 to 2 cups daily. European
Mistletoe wine dosage is 3 to 4 glasses daily, liquid extract
dosage is 1 to 3 ml 3 times daily, and the tincture dosage is
0.5 ml 3 times daily.The dosage for the treatment of hypertonia and as an
arteriosclerotic prophylactic is 2 to 6 gm of European
Mistletoe powder 3 times daily by mouth.Storage: European Mistletoe must be stored away from the
light over an appropriate drying agent.
LITERATURE
EUROPEAN MISTLETOE FRUIT
Frohne D, Pfander HJ, Giftpflanzen - Ein Handbuch fur
Apotheker, Toxikologen und Biologen, 4. Aufl., Wiss. Verlags-
Ges. Stuttgart 1997.
Hansel R, Keller K, Rimpler H, Schneider G (Hrsg.), Hagers
Handbuch der Pharmazeutischen Praxis, 5. Aufl., Bde 4-6
(Drogen): Springer Verlag Berlin, Heidelberg, New York, 1992-
1994.
Teuscher E. Lindequist U. Biogene Gifte - Biologie, Chemie,
Pharmakologie, 2. Aufl.. Fischer Verlag Stuttgart 1994.
EUROPEAN MISTLETOE HERB AND STEM
Anonym, Allergie auf Mistelextrakt. In: ZPT 13(3):96. 1992.
Anonym, Die Mistel. In: DAZ 136(48):4330-4332. 1996.
Anonym, Integrative Konzepte in der Onkologie: Misteltherapie
(S. 19). In: NGM Suppl. 1/94:1-36. 1994.
Anonym, Misteltherapie aus schulmedizinischer Sicht. In: DAZ
131(37):1894. 1991.
Anonym, Optimale Misteldosierung. In: PZ 140(35):3082. 1995.
Anonym, Phytotherapie: Einsatz von Mistelextrakten in der
Tumortherapie. In: DAZ 135(1):73. 1995.
Anonym, Sind Mistelpraparate mehr als nur Adjuvanzien in der
onkologischen Therapie? In: ZPT 15(6):353-355. 1994.
Becker H, Exner J, (1980) Z Pflanzenphysiol. 97
Berg P, Stein G, Ein Inhaltsstoff allein geniigt nicht, s. auch
folgenden Artikel. In: ZPT 16(5):282. 1995.
Beuth HJ, Mistel: "In der Onkologie nur Praparate einsetzen,
die auf Mistellektin standardisiert sind!" In: ZPT 16(1):40-41.
1995.
Beuth J, Ko HL, Gabius HJ, Burrichter H, Oette K, Pulverer
G, (1992) Behavior of lymphocyte subsets, expression of
activation markers in response to immunotherapy with
galactoside-specific lectin from Mistletoe in breast cancer. Clin
Invest 70:658-661
Beuth J, Ko HL, Pulverer G, Angewandte Lektinologie. In:
DAZ 134(25):2331. 1994.
Beuth J, Lenartz D, Uhlenbruck G, Lektionoptimierter
Mistelextrakt. In: ZPT 18(2):85-91. 1997.
Bloksma N et al., (1982) Planta Med 46:221.
Dumont S et al., Lectins from Mistletoe (Viscum album L.)
induce the production of cytokines by cultured human
monocytes. In: PM 61 (Abstracts of 43rd Ann Congr):57. 1995.
Franz G, Phytotherapie in der Tumorbehandlung. In: DAZ
130(26): 1443. 1990.
Franz H, (1985) Pharmazie 40(2):97.
Franz H et al., (1981) Biochem J 195:481.
Gabius HJ, Gabius S, Die Misteltherapie auf dem
naturwissenschaftlichen Priifstand. In: PZ 139(22): 1745. 1994.
Hamacher H, Mistel (Viscum album L.) - Forschung und
therapeutische Anwendung. In: ZPT 18(l):34-35. 1997.